High-Load Core@Shell Nanocarriers with Irinotecan and 5-Fluorouracil for Combination Chemotherapy in Colorectal Cancer

被引:0
作者
Notter, Silke [1 ]
Choezom, Dolma [2 ,3 ,4 ]
Griebel, Titus [2 ,3 ]
Ramos-Gomes, Fernanda [3 ]
Moebius, Wiebke [3 ]
De Oliveira, Tiago [4 ]
Conradi, Lena-Christin [4 ]
Alves, Frauke [2 ,3 ,5 ]
Feldmann, Claus [1 ]
机构
[1] Karlsruhe Inst Technol KIT, Inst Inorgan Chem, Engesserstr 15, D-76131 Karlsruhe, Germany
[2] Univ Med Ctr Goettingen UMG, Clin Haematol & Med Oncol, Robert Koch Str 40, D-37075 Gottingen, Germany
[3] Max Planck Inst Multidisciplinary Sci MPI NAT, Dept Neurogenet, City Campus,Hermann Rein Str 3, D-37075 Gottingen, Germany
[4] Univ Med Ctr Goettingen UMG, Dept Gen Visceral & Pediat Surg, Robert Koch Str 40, D-37075 Gottingen, Germany
[5] Univ Med Ctr Goettingen UMG, Inst Diagnost & Intervent Radiol, Robert Koch Str 40, D-37075 Gottingen, Germany
来源
SMALL SCIENCE | 2024年 / 4卷 / 11期
关键词
5-fluorouracil; colorectal cancer; drug delivery; irinotecan; tumor combination therapy; DRUG-DELIVERY; NANOPARTICLES; PACLITAXEL; PROGRESS; TRIAL;
D O I
10.1002/smsc.202400196
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Colorectal cancer (CRC) is the third most common cancer type and second leading cause of cancer-related deaths worldwide, requiring novel drug-delivery concepts. ITC@ZrO(TocP)/ZrO(FdUMP) core@shell nanocarriers (designated ITC-FdUMP-NC) with the clinically relevant chemotherapeutics irinotecan (ITC) and fluoro-2 '-deoxyuridine-5 '-phosphate (FdUMP) (active derivative of 5 '-fluorouracil/5-FU) are a new type of nanocarrier with high drug payload (22 wt% of lipophilic ITC: particle core; 10 wt% of hydrophilic FdUMP: particle shell). The nanocarriers are tested in different CRC cell lines, a normal cell line, and rectal cancer patient-derived organoids (PDOs). Fluorescence-labeled nanocarriers show efficient uptake by all CRC cells and allow to distinctly track the intracellular trafficking toward endolysosomal compartments. Although free chemotherapeutic drugs exhibit a greater potency in 2D cell cultures, ITC-FdUMP-NC demonstrate equivalent cytotoxic efficacies as the freely dissolved drugs in the more complex 3D rectal cancer PDOs. The sustained drug-release profile of the nanocarriers contrasts favorably with conventional free drugs, potentially enhancing the therapeutic outcome in vivo. With a chemotherapeutic cocktail comparable to the clinically applied FOLFIRI (ITC + 5-FU), the ITC-FdUMP-NC represent a novel type of nanocarrier with high anti-tumor effect and high drug payload, offering a promising strategy to circumvent chemoresistance and to improve therapy efficacy in vivo with less side effects. A clinically relevant drug cocktail of irinotecan (ITC) and 5-fluorouridine (5-FU) is combined in a single nanocarrier with high drug payload (32%). The nanocarriers show efficient uptake and high efficacy in different human colon cancer and human rectal cancer cell lines as well as rectal cancer patient-derived organoids, also allowing to elucidate the membrane-trafficking pathway.image (c) 2024 WILEY-VCH GmbH
引用
收藏
页数:14
相关论文
共 50 条
  • [31] A phase I trial of CPT-11 in combination with 5-fluorouracil plus leucovorin chemotherapy for patients with metastatic colorectal cancer
    Yamaguchi, Y
    Minami, K
    Kawabuchi, Y
    Emi, M
    HEPATO-GASTROENTEROLOGY, 2006, 53 (68) : 201 - 205
  • [32] Response to chemotherapy (irinotecan plus 5-fluorouracil) in colorectal carcinoma can be predicted by tumour DNA content
    Bendardaf, R
    Lamlum, H
    Ristamäki, R
    Ålgars, A
    Collan, Y
    Pyrhönen, S
    ONCOLOGY, 2004, 66 (01) : 46 - 52
  • [33] Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer
    Ji, SH
    Park, YS
    Lee, J
    Lim, DH
    Park, BB
    Park, KW
    Kang, JH
    Lee, SH
    Park, JO
    Kim, K
    Kim, WS
    Jung, CW
    Im, YH
    Kang, WK
    Park, K
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 35 (04) : 214 - 217
  • [34] Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer
    Levy-Piedbois, C
    Durand-Zaleski, I
    Juhel, H
    Schmitt, C
    Bellanger, A
    Piedbois, P
    ANNALS OF ONCOLOGY, 2000, 11 (02) : 157 - 161
  • [35] Bevacizumab in combination with irinotecan, 5-fluorouracil and leucovorin given as first-line treatment of metastatic colorectal cancer
    Rocha, Jose Aurillo
    ANTI-CANCER DRUGS, 2011, 22 : S9 - S13
  • [36] Evaluation of the 5-fluorouracil plasma level in patients with colorectal cancer undergoing continuous infusion chemotherapy
    Abe, Yu
    Sakuyama, Naoki
    Sato, Tsuyoshi
    Kishine, Kenji
    Nagayasu, Kiichi
    Nakatani, Akinori
    Kitajima, Masayuki
    Watanabe, Tomoo
    Nishimura, Kazuhiko
    Ochiai, Takumi
    Nagaoka, Isao
    MOLECULAR AND CLINICAL ONCOLOGY, 2019, 11 (03) : 289 - 295
  • [37] Regional administration of irinotecan in combination with 5-fluorouracil and leucovorin in patients with colorectal cancer liver metastases -: A plot experience
    Melichar, B
    Dvorák, J
    Jandík, P
    Tousková, M
    Malírová, E
    Megancová, J
    Voboril, Z
    HEPATO-GASTROENTEROLOGY, 2001, 48 (42) : 1721 - 1726
  • [38] Impact of 5-fluorouracil metabolizing enzymes on chemotherapy in patients with resectable colorectal cancer
    Ochiai, Takumi
    Umeki, Masahiko
    Miyake, Hiroshi
    Iida, Tatsumi
    Okumura, Minoru
    Ohno, Kazuhide
    Sakamoto, Masashi
    Miyoshi, Nobukazu
    Takahashi, Masahiko
    Tsumura, Hldenori
    Tokunaga, Yukihiko
    Naitou, Haruhiko
    Fukui, Takuji
    ONCOLOGY REPORTS, 2014, 32 (03) : 887 - 892
  • [39] Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer
    Rogers, Jane E.
    Xiao, Lianchun
    Trail, Allison
    Blum Murphy, Mariela
    Palmer, Melissa
    Ajani, Jaffer A.
    ONCOLOGY, 2020, 98 (05) : 289 - 294
  • [40] Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer -: A feasibility pilot study
    Calvo, E
    Cortés, J
    González-Cao, M
    Rodríguez, J
    Aramendía, JM
    Fernández-Hidalgo, O
    Martín-Algarra, S
    Salgado, JE
    Martínez-Monge, R
    de Irala, J
    Brugarolas, A
    ONCOLOGY, 2002, 63 (03) : 254 - 265